© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
It’s been a good year for heart failure research … mostly
EXPERT ANALYSIS FROM ACC 17
Related Articles
Some diabetes drugs may lower risk of severe COVID-19 outcomes
April 13, 2017
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
![1]()
Empagliflozin cut PA pressures in heart failure patients
April 13, 2017
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time.
![1]()
Cost of preventable adult hospital stays topped $33 billion in 2017
April 13, 2017
Heart failure, diabetes, and COPD were the most expensive preventable conditions.
New study of diabetes drug for COVID-19 raises eyebrows
April 13, 2017
Some question the safety of AstraZeneca’s just-launched DARE-19 study testing whether dapagliflozin will reduce adverse outcomes of COVID-19.
